| 本文已被：浏览 333次 下载 155次 |
码上扫一扫！ |
|
|
| 麝香保心丸联合西医常规治疗冠心病心绞痛的回顾性队列研究 |
|
郭瑞莹1,2, 刘昳佳3, 王朔1,4, 李琳1, 刘凡凡1, 徐强5, 于春泉1
|
|
1.天津中医药大学, 天津 301617;2.天津中医药大学第一附属医院, 天津 300381;3.天津中医药大学第二附属医院康复科, 天津 300250;4.天津大学胸科医院, 天津 300222;5.天津中医药大学第二附属医院心内科, 天津 300250
|
|
| 摘要: |
| 目的 评估麝香保心丸联合标准化西医方案治疗冠心病心绞痛的综合疗效，明确其治疗优势。方法 基于多中心真实世界临床数据，采用回顾性队列研究方法，纳入2014年1月—2022年6月天津市6所三级医院收治的冠心病心绞痛患者。通过1∶1匹配将940例受试者分为暴露组（麝香保心丸联合标准治疗）与非暴露组（单用标准治疗），每组470例。主要观察终点为住院期间心血管事件发生率、临床生化指标及颈部血管彩超。结果 暴露组肌酸激酶、天冬氨酸氨基转移酶、乳酸脱氢酶、血糖、糖化血红蛋白、凝血酶时间、D-二聚体、总胆固醇、肌酐、白蛋白、丙氨酸氨基转移酶、总胆红素、血小板水平低于非暴露组，颈动脉内中膜厚度、颈动脉斑块检出率低于非暴露组，差异具有统计学意义（P＜0.05）。结论 麝香保心丸联合标准化西医方案治疗的冠心病心绞痛患者心血管事件发生率较低，凝血功能、心肌酶、肾功能、肝功能、血糖、血脂水平较稳定，颈动脉内中膜厚度较小，斑块发生率较低。 |
| 关键词: 心绞痛 麝香保心丸 回顾性 队列研究 |
| DOI：10.11656/j.issn.1673-9043.2025.09.03 |
| 分类号:R541.4 |
| 基金项目:横向课题-麝香保心丸治疗冠心病心绞痛回顾性队列研究（HX2020-39）；河北省中医药类科学研究课题计划项目（T2025076）；国家自然科学基金资助项目（82104565）；现代中医药海河实验室2023年度第二批“揭榜挂帅”科技项目（24HHZYSS00016）。 |
|
| Retrospective cohort study of Shexiang Baoxin Pills combined with Western medicine in the treatment of angina pectoris |
|
GUO Ruiying1,2, LIU Yijia3, WANG Shuo1,4, LI Lin1, LIU Fanfan1, XU Qiang5, YU Chunquan1
|
|
1.Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China;2.First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300381, China;3.Department of Rehabilitation, The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China;4.Tianjin University Chest Hospital, Tianjin 300222, China;5.Department of Cardiology, The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China
|
| Abstract: |
| Objective To evaluate the comprehensive efficacy of Shexiang Baoxin Pills combined with standardized Western medical treatment for angina pectoris due to coronary heart disease and clarify its therapeutic advantages. Methods Based on multi-center real-world clinical data, a retrospective cohort study was conducted. Patients with angina pectoris due to coronary heart disease admitted to six tertiary hospitals in Tianjin from January 2014 to June 2022 were included. Through 1∶1 matching, 940 subjects were divided into the exposure group(Shexiang Baoxin Pills combined with standard treatment) and the non-exposure group(standard treatment alone), with 470 cases in each group. The primary endpoints were the incidence of cardiovascular events during hospitalization, clinical biochemical indicators, and color Doppler ultrasound of the carotid arteries. Results The levels of creatine kinase, aspartate aminotransferase, lactate dehydrogenase, blood glucose, glycated hemoglobin, thrombin time, D-dimer, total cholesterol, creatinine, albumin, alanine aminotransferase, total bilirubin, and platelets in the exposure group were significantly lower than those in the non-exposure group, and the carotid intima-media thickness and the detection rate of carotid plaques were significantly lower in the exposure group, with statistically significant differences(P < 0.05). Conclusion Patients with angina pectoris due to coronary heart disease treated with Shexiang Baoxin Pills combined with standardized Western medical treatment have a lower incidence of cardiovascular events, more stable coagulation function, myocardial enzymes, renal function, liver function, blood glucose, and lipid levels, and smaller carotid intima-media thickness and lower plaque occurrence rate. |
| Key words: angina pectoris Shexiang Baoxin Pills retrospective cohort study |
